NIAID backs Emergent work; Antigenics reports a loss;

Vaccine Research

The NIAID has provided $4.5 million in research grants to Emergent BioSolutions for its work on vaccines for botulism and anthrax. Report

Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Release

Avantogen has been moving to acquire a majority of Hawaii Biotech, attracted by approaching Phase I trials for new West Nile disease and dengue fever vaccines. Report

Medical Marketing International has raised £1 million to fund research on a cancer vaccine and other work. Story

Vaccine market

Antigenics, which is marketing the cancer vaccine Oncophage in Russia, reported a net loss of $12.2 million in the last quarter. Release

Scotland has launched a campaign to raise awareness of the new vaccine for cervical cancer. Story

Physicians in Florida are reporting a spike in the number of whooping cough cases. Story

UK officials say they have had to destroy almost half a million doses of vaccine which had expired. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.